Structure Therapeutics IncNASDAQ:GPCR
- LAST PRICE33.1500
- TODAY'S CHANGE (%)-0.6000 (-1.7778%)
- Bid / Lots33.1600/ 1
- Ask / Lots33.6400/ 3
- Open / Previous Close33.7800 / 33.7500
- Day Range
- 52 Week Range
- Volume240,485
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GPCR |
|---|---|---|
| 09:32 ET | 1758 | 34.395 |
| 09:33 ET | 100 | 34.19 |
| 09:35 ET | 3609 | 34.361 |
| 09:37 ET | 400 | 34.29 |
| 09:39 ET | 810 | 34.26 |
| 09:42 ET | 4828 | 34.01 |
| 09:44 ET | 5005 | 34.31 |
| 09:46 ET | 100 | 34.24 |
| 09:48 ET | 1360 | 34.11 |
| 09:50 ET | 200 | 34.11 |
| 09:51 ET | 400 | 34.01 |
| 09:53 ET | 200 | 34.01 |
| 09:55 ET | 800 | 34.15 |
| 09:57 ET | 228 | 34.226 |
| 10:00 ET | 371 | 33.885 |
| 10:04 ET | 200 | 33.81 |
| 10:06 ET | 200 | 33.94 |
| 10:08 ET | 485 | 33.81 |
| 10:09 ET | 100 | 33.94 |
| 10:11 ET | 346 | 33.76 |
| 10:13 ET | 400 | 33.84 |
| 10:15 ET | 100 | 33.81 |
| 10:18 ET | 300 | 33.84 |
| 10:20 ET | 200 | 33.88 |
| 10:22 ET | 625 | 33.76 |
| 10:24 ET | 4053 | 33.57 |
| 10:26 ET | 1000 | 33.51 |
| 10:27 ET | 1701 | 33.5257 |
| 10:29 ET | 923 | 33.61 |
| 10:31 ET | 1000 | 33.53 |
| 10:33 ET | 300 | 33.53 |
| 10:36 ET | 300 | 33.56 |
| 10:38 ET | 396 | 33.55 |
| 10:40 ET | 982 | 33.5636 |
| 10:42 ET | 9967 | 33.3394 |
| 10:44 ET | 100 | 33.38 |
| 10:45 ET | 110 | 33.37 |
| 10:47 ET | 300 | 33.4899 |
| 10:49 ET | 300 | 33.39 |
| 10:51 ET | 100 | 33.4294 |
| 10:56 ET | 598 | 33.39 |
| 10:58 ET | 100 | 33.325 |
| 11:00 ET | 200 | 33.31 |
| 11:02 ET | 500 | 33.4386 |
| 11:05 ET | 100 | 33.37 |
| 11:07 ET | 985 | 33.43 |
| 11:09 ET | 200 | 33.42 |
| 11:12 ET | 200 | 33.395 |
| 11:18 ET | 700 | 33.29 |
| 11:20 ET | 802 | 33.17 |
| 11:21 ET | 500 | 33.12 |
| 11:25 ET | 400 | 33.17 |
| 11:27 ET | 439 | 33.1829 |
| 11:30 ET | 100 | 33.2 |
| 11:32 ET | 100 | 33.18 |
| 11:34 ET | 204 | 33.29 |
| 11:36 ET | 566 | 33.2 |
| 11:39 ET | 404 | 33.02 |
| 11:41 ET | 2612 | 33.02 |
| 11:43 ET | 1378 | 33.058 |
| 11:50 ET | 1670 | 33.08 |
| 11:52 ET | 193 | 33.09 |
| 11:54 ET | 208 | 33.125 |
| 11:56 ET | 500 | 33.24 |
| 11:57 ET | 270 | 33.15 |
| 11:59 ET | 1181 | 33.05 |
| 12:01 ET | 3611 | 32.94 |
| 12:03 ET | 400 | 32.97 |
| 12:06 ET | 3100 | 32.9868 |
| 12:08 ET | 4839 | 32.92 |
| 12:10 ET | 1600 | 32.905 |
| 12:12 ET | 2510 | 32.945 |
| 12:15 ET | 260 | 32.975 |
| 12:17 ET | 300 | 33.02 |
| 12:19 ET | 506 | 32.955 |
| 12:21 ET | 27854 | 33.2 |
| 12:24 ET | 600 | 33.13 |
| 12:26 ET | 400 | 33.13 |
| 12:28 ET | 500 | 33.21 |
| 12:30 ET | 100 | 33.13 |
| 12:32 ET | 1985 | 33.22 |
| 12:33 ET | 1317 | 33.325 |
| 12:35 ET | 400 | 33.3 |
| 12:37 ET | 2719 | 33.3 |
| 12:39 ET | 1500 | 33.29 |
| 12:42 ET | 1721 | 33.29 |
| 12:44 ET | 18644 | 33.215 |
| 12:46 ET | 600 | 33.25 |
| 12:48 ET | 900 | 33.24 |
| 12:50 ET | 25200 | 33.27 |
| 12:51 ET | 2600 | 33.34 |
| 12:53 ET | 1300 | 33.12 |
| 12:55 ET | 1433 | 33.06 |
| 12:57 ET | 2210 | 33 |
| 01:00 ET | 19089 | 33.15 |
Nov 15, 2024
Structure Therapeutics to Participate in the Jefferies London Healthcare Conference, from 8:30AM ET on Friday Nov 15, 2024 by Dow Jones
8:30AM ET on Friday Nov 15, 2024 by Dow Jones
Nov 13, 2024
Press Release: Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights, from 4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
4:05PM ET on Wednesday Nov 13, 2024 by Dow JonesStructure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights, from 4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
4:05PM ET on Wednesday Nov 13, 2024 by Dow JonesStructure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity, from 4:01PM ET on Wednesday Nov 13, 2024 by Dow Jones
4:01PM ET on Wednesday Nov 13, 2024 by Dow Jones
Oct 31, 2024
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek(R) 2024, from 8:30AM ET on Thursday Oct 31, 2024 by Dow Jones
8:30AM ET on Thursday Oct 31, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Structure Therapeutics Inc | 1.9B | -15.0x | --- |
Disc Medicine Inc | 1.9B | -16.0x | --- |
NewAmsterdam Pharma Company NV | 1.9B | -8.9x | --- |
Celldex Therapeutics Inc | 1.9B | -10.7x | --- |
Belite Bio Inc | 2.1B | -57.3x | --- |
Tarsus Pharmaceuticals Inc | 1.9B | -13.9x | --- |
Company Information
Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases. It is focused on G-protein coupled receptors (GPCRs) as a therapeutic target class. Its product candidates include GSBR-1290, Amylin, glucose-dependent insulinotropic polypeptide receptor (GIPR), GCGR, ANPA-0073 and LTSE-2578. It is developing GSBR-1290, its oral small molecule product candidate targeting the validated glucagon-like-peptide-1 receptor (GLP-1R) for the treatment of type 2 diabetes mellitus (T2DM) and obesity. It is developing GLP-1R candidates, including dual GLP-1R/GIPR agonists and amylin agonists, each designed with customized properties to achieve additional benefit. It is developing ANPA-0073, an investigational oral small molecule APJR agonist, for the treatment of idiopathic pulmonary fibrosis (IPF). It is evaluating its LPA1R program, LTSE-2578 for IPF and progressive pulmonary fibrosis.
Contact Information
- Headquarters
- 611 Gateway Blvd Suite 223SOUTH SAN FRANCISCO, CA, United States 94080
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Daniel Welch
- Chief Executive Officer, Director
- Raymond Stevens
- Chief Financial Officer
- Jun Yoon
- Chief Technology Officer
- Yingli Ma
- Chief Scientific Officer
- Xichen Lin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.9B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 57.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.21 |
Book Value | $9.76 |
P/E Ratio | -15.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
